[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR11580A - Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf - Google Patents

Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf

Info

Publication number
CR11580A
CR11580A CR11580A CR11580A CR11580A CR 11580 A CR11580 A CR 11580A CR 11580 A CR11580 A CR 11580A CR 11580 A CR11580 A CR 11580A CR 11580 A CR11580 A CR 11580A
Authority
CR
Costa Rica
Prior art keywords
klotho
compositions
methods
fusion polypeptides
fgf fusion
Prior art date
Application number
CR11580A
Other languages
English (en)
Inventor
David Glass
Shou-Ih Hu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11580A publication Critical patent/CR11580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invencion se refiere a metodos, kits, y composiciones para prevenir o tratar condiciones relacionadas con la edad o trastornos metabolicos. Los polipeptidos de fusion Klotho de la invencion incluyen cuando menos una proteina Klotho o un fragmento activo de la misma. Las proteinas de fusion Klotho son utiles en el tratamiento y en la prevencion de una variedad de condiciones relacionadas con la edad y trastornos metabolicos.
CR11580A 2008-01-28 2010-07-21 Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf CR11580A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6301508P 2008-01-28 2008-01-28

Publications (1)

Publication Number Publication Date
CR11580A true CR11580A (es) 2010-10-05

Family

ID=40492768

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11580A CR11580A (es) 2008-01-28 2010-07-21 Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf

Country Status (21)

Country Link
US (2) US8481031B2 (es)
EP (1) EP2247614B1 (es)
JP (1) JP5627469B2 (es)
KR (1) KR20100118126A (es)
CN (1) CN102015760B (es)
AR (1) AR070690A1 (es)
AU (1) AU2009209696B2 (es)
BR (1) BRPI0906722A2 (es)
CA (2) CA2854933A1 (es)
CL (1) CL2009000166A1 (es)
CO (1) CO6300826A2 (es)
CR (1) CR11580A (es)
EA (1) EA201001204A1 (es)
EC (1) ECSP10010372A (es)
ES (1) ES2479417T3 (es)
IL (1) IL207161A0 (es)
MA (1) MA32031B1 (es)
MX (1) MX2010008206A (es)
PE (1) PE20091405A1 (es)
TW (1) TW200936156A (es)
WO (1) WO2009095372A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
JO3469B1 (ar) * 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2512500A1 (en) 2009-12-16 2012-10-24 Eli Lilly and Company Therapeutic uses of soluble alpha-klotho
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
LT2571510T (lt) * 2010-05-21 2018-11-12 Xl-Protein Gmbh Biosintetiniai prolino (alanino) statistinės spiralės polipeptidai ir jų panaudojimas
RS62520B1 (sr) * 2010-06-25 2021-11-30 Shire Human Genetic Therapies Metode i kompozicije za isporuku cns iduronata-2-sulfataze
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013027191A1 (en) * 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
TWI478002B (zh) * 2012-02-09 2015-03-21 Univ Nat Sun Yat Sen 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2895517C (en) 2012-12-27 2022-10-11 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6159930B2 (ja) * 2013-10-24 2017-07-12 地方独立行政法人東京都健康長寿医療センター 筋幹細胞又は筋芽細胞、及びそれを用いた代謝変換に関与する物質のスクリーニング方法、並びにスクリーニング方法によって得られた物質を含む医薬組成物
AU2014342630B2 (en) 2013-10-28 2020-11-05 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
SG11201606018UA (en) 2014-01-24 2016-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
JP2017517272A (ja) 2014-03-28 2017-06-29 ニューヨーク・ユニバーシティ Ｆｇｆ２３融合タンパク質
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20170084332A (ko) * 2014-12-04 2017-07-19 노파르티스 아게 Klotho 변이체 폴리펩티드를 사용하는 방법 및 조성물
CN105838661B (zh) * 2014-12-30 2020-11-10 深圳市第二人民医院 Klotho基因编辑在异种肾脏移植中的应用
CA2974988A1 (en) 2015-02-06 2016-08-11 The Regents Of The University Of California Methods and compositions for improved cognition
EP3262159B1 (en) * 2015-02-27 2019-07-24 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cell expressing klotho
US11491115B2 (en) * 2015-07-09 2022-11-08 The Board Of Regents Of The University Of Texas System Nanoparticles containing extracellular matrix for drug delivery
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
KR20230125857A (ko) * 2016-06-02 2023-08-29 클로토 테라퓨틱스, 아이엔씨. 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물및 방법
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
BR112019010250A2 (pt) * 2016-11-22 2019-09-17 Klotho Therapeutics Inc novas proteínas klotho recombinantes e composições e métodos que envolvem as mesmas
CN110997726B (zh) 2017-07-06 2024-10-29 耶鲁大学 治疗或预防内分泌fgf-关联疾病的组合物和方法
AU2018378802B2 (en) * 2017-12-06 2024-08-15 Klotho Therapeutics, Inc. Products and methods for assessing and increasing Klotho protein levels
CN111712519A (zh) * 2017-12-13 2020-09-25 耶鲁大学 用于治疗或预防内分泌fgf23-相关疾病的组合物和方法
CN108434441A (zh) * 2018-04-17 2018-08-24 哈尔滨博翱生物医药技术开发有限公司 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用
CN109722480B (zh) * 2018-05-17 2022-04-26 上海交通大学 一种非小细胞肺癌检测试剂盒及其应用
WO2019236603A1 (en) 2018-06-08 2019-12-12 Saint Louis University Methods and compositions for treating decreased cognitive ability
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406A (en) 1849-05-01 Artificial teeth
US853A (en) 1838-07-24 Jesse reed
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
WO1991019810A1 (en) 1990-06-15 1991-12-26 California Biotechnology Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5541094A (en) 1992-09-25 1996-07-30 E. I. Du Pont De Nemours And Company Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US6194177B1 (en) 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
US6358752B1 (en) 1996-09-27 2002-03-19 Cornell Research Foundation, Inc. Liposome-enhanced test device and method
AU739057B2 (en) 1996-12-26 2001-10-04 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Novel polypeptide, novel DNA, and novel antibody
US6127598A (en) 1997-07-25 2000-10-03 The Regents Of The University Of California NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6537749B2 (en) 1998-04-03 2003-03-25 Phylos, Inc. Addressable protein arrays
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
AU4469300A (en) 1999-04-22 2000-11-10 Lipomed, Inc. Nmr-method for determining the risk of developing type 2 diabetes
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
WO2002008271A1 (en) 2000-07-19 2002-01-31 Advanced Research & Technology Institute Novel fibroblast growth factor (fgf23) and methods for use
CA2436661A1 (en) 2001-01-30 2002-08-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide molecules
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
JP2006158339A (ja) * 2004-12-09 2006-06-22 Kyoto Univ βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Also Published As

Publication number Publication date
CA2712634C (en) 2014-09-16
US20130324458A1 (en) 2013-12-05
EA201001204A1 (ru) 2011-02-28
PE20091405A1 (es) 2009-10-07
WO2009095372A1 (en) 2009-08-06
US9458209B2 (en) 2016-10-04
AU2009209696B2 (en) 2012-04-19
CN102015760A (zh) 2011-04-13
US20090192087A1 (en) 2009-07-30
CO6300826A2 (es) 2011-07-21
JP2011510620A (ja) 2011-04-07
CL2009000166A1 (es) 2010-12-24
BRPI0906722A2 (pt) 2015-07-07
IL207161A0 (en) 2010-12-30
EP2247614B1 (en) 2014-04-09
MX2010008206A (es) 2010-08-10
ES2479417T3 (es) 2014-07-24
TW200936156A (en) 2009-09-01
US8481031B2 (en) 2013-07-09
AU2009209696A1 (en) 2009-08-06
MA32031B1 (fr) 2011-01-03
ECSP10010372A (es) 2010-08-31
CN102015760B (zh) 2014-06-11
CA2712634A1 (en) 2009-08-06
CA2854933A1 (en) 2009-08-06
EP2247614A1 (en) 2010-11-10
KR20100118126A (ko) 2010-11-04
AR070690A1 (es) 2010-04-28
JP5627469B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CR10347A (es) Anticuerpos contra el peptidob-amiloide
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
EA201001639A1 (ru) Композиции и способы их получения и применения
AR058182A1 (es) Metodos, composiciones y equipos par el tratamiento de afecciones medicas
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201001372A1 (ru) Формы рифаксимина и их применение
EA201170349A1 (ru) Модуляторы mif
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
CO6602146A2 (es) Uso combinado de proteínas cryda y cry1fa para el manejo de la resistencia de los insectos
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)